Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016
Identifieur interne : 000736 ( Pmc/Checkpoint ); précédent : 000735; suivant : 000737Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016
Auteurs : Birgitte K. Giersing [Suisse] ; Johan Vekemans [Suisse] ; Samantha Nava [États-Unis] ; David C. Kaslow [États-Unis] ; Vasee Moorthy [Suisse]Source :
- Vaccine [ 0264-410X ] ; 2017.
Abstract
The third meeting of WHO’s Product Development for Vaccines Advisory Committee (PDVAC) was held in June 2016, with a remit to revisit the pathogen areas for which significant progress has occurred since recommendations from the 2015 meeting, as well as to consider new advances in the development of vaccines against other pathogens. Since the previous meeting, significant progress has been made with regulatory approvals of the first malaria and dengue vaccines, and the first phase III trials of a respiratory syncytial virus (RSV) vaccine candidate has started in the elderly and pregnant women. In addition, PDVAC has also supported vaccine development efforts against important emerging pathogens, including Middle Eastern Coronavirus (MERS CoV) and Zika virus. Trials of HIV and tuberculosis vaccine candidates are steadily progressing towards pivotal data points, and the leading norovirus vaccine candidate has entered a phase IIb efficacy study. WHO’s Immunization, Vaccine and Biologicals (IVB) department is actively working in several pathogen areas on the recommendation of PDVAC, as well as continuing horizon scanning for advances in the development of vaccines that may benefit low and middle income countries (LMICs), such as the recent licensure of the enterovirus 71 (EV71) vaccine in China. Following on from discussions with WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization, PDVAC will also look beyond licensure and consider data needs for vaccine recommendation and implementation to reduce the delay between vaccine approval and vaccine impact.
Url:
DOI: 10.1016/j.vaccine.2016.10.090
PubMed: 28262332
PubMed Central: 7131228
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:7131228Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016</title><author><name sortKey="Giersing, Birgitte K" sort="Giersing, Birgitte K" uniqKey="Giersing B" first="Birgitte K." last="Giersing">Birgitte K. Giersing</name><affiliation wicri:level="1"><nlm:aff id="af005">Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author><author><name sortKey="Vekemans, Johan" sort="Vekemans, Johan" uniqKey="Vekemans J" first="Johan" last="Vekemans">Johan Vekemans</name><affiliation wicri:level="1"><nlm:aff id="af005">Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author><author><name sortKey="Nava, Samantha" sort="Nava, Samantha" uniqKey="Nava S" first="Samantha" last="Nava">Samantha Nava</name><affiliation wicri:level="2"><nlm:aff id="af010">University of Texas Medical Branch, Galveston, TX, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Medical Branch, Galveston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Kaslow, David C" sort="Kaslow, David C" uniqKey="Kaslow D" first="David C." last="Kaslow">David C. Kaslow</name><affiliation wicri:level="2"><nlm:aff id="af015">PATH, Seattle, WA 98109, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Moorthy, Vasee" sort="Moorthy, Vasee" uniqKey="Moorthy V" first="Vasee" last="Moorthy">Vasee Moorthy</name><affiliation wicri:level="1"><nlm:aff id="af005">Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28262332</idno><idno type="pmc">7131228</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131228</idno><idno type="RBID">PMC:7131228</idno><idno type="doi">10.1016/j.vaccine.2016.10.090</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">000931</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000931</idno><idno type="wicri:Area/Pmc/Curation">000931</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000931</idno><idno type="wicri:Area/Pmc/Checkpoint">000736</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000736</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016</title><author><name sortKey="Giersing, Birgitte K" sort="Giersing, Birgitte K" uniqKey="Giersing B" first="Birgitte K." last="Giersing">Birgitte K. Giersing</name><affiliation wicri:level="1"><nlm:aff id="af005">Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author><author><name sortKey="Vekemans, Johan" sort="Vekemans, Johan" uniqKey="Vekemans J" first="Johan" last="Vekemans">Johan Vekemans</name><affiliation wicri:level="1"><nlm:aff id="af005">Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author><author><name sortKey="Nava, Samantha" sort="Nava, Samantha" uniqKey="Nava S" first="Samantha" last="Nava">Samantha Nava</name><affiliation wicri:level="2"><nlm:aff id="af010">University of Texas Medical Branch, Galveston, TX, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Medical Branch, Galveston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Kaslow, David C" sort="Kaslow, David C" uniqKey="Kaslow D" first="David C." last="Kaslow">David C. Kaslow</name><affiliation wicri:level="2"><nlm:aff id="af015">PATH, Seattle, WA 98109, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Moorthy, Vasee" sort="Moorthy, Vasee" uniqKey="Moorthy V" first="Vasee" last="Moorthy">Vasee Moorthy</name><affiliation wicri:level="1"><nlm:aff id="af005">Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><idno type="eISSN">1873-2518</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The third meeting of WHO’s Product Development for Vaccines Advisory Committee (PDVAC) was held in June 2016, with a remit to revisit the pathogen areas for which significant progress has occurred since recommendations from the 2015 meeting, as well as to consider new advances in the development of vaccines against other pathogens. Since the previous meeting, significant progress has been made with regulatory approvals of the first malaria and dengue vaccines, and the first phase III trials of a respiratory syncytial virus (RSV) vaccine candidate has started in the elderly and pregnant women. In addition, PDVAC has also supported vaccine development efforts against important emerging pathogens, including Middle Eastern Coronavirus (MERS CoV) and Zika virus. Trials of HIV and tuberculosis vaccine candidates are steadily progressing towards pivotal data points, and the leading norovirus vaccine candidate has entered a phase IIb efficacy study. WHO’s Immunization, Vaccine and Biologicals (IVB) department is actively working in several pathogen areas on the recommendation of PDVAC, as well as continuing horizon scanning for advances in the development of vaccines that may benefit low and middle income countries (LMICs), such as the recent licensure of the enterovirus 71 (EV71) vaccine in China. Following on from discussions with WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization, PDVAC will also look beyond licensure and consider data needs for vaccine recommendation and implementation to reduce the delay between vaccine approval and vaccine impact.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Lipsitch, M" uniqKey="Lipsitch M">M. Lipsitch</name></author><author><name sortKey="Siber, G R" uniqKey="Siber G">G.R. Siber</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Knight, G M" uniqKey="Knight G">G.M. Knight</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Evans, T G" uniqKey="Evans T">T.G. Evans</name></author><author><name sortKey="Schrager, L" uniqKey="Schrager L">L. Schrager</name></author><author><name sortKey="Thole, J" uniqKey="Thole J">J. Thole</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rerks Ngarm, S" uniqKey="Rerks Ngarm S">S. Rerks-Ngarm</name></author><author><name sortKey="Pitisuttithum, P" uniqKey="Pitisuttithum P">P. Pitisuttithum</name></author><author><name sortKey="Nitayaphan, S" uniqKey="Nitayaphan S">S. Nitayaphan</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Lopman, B A" uniqKey="Lopman B">B.A. Lopman</name></author><author><name sortKey="Steele, D" uniqKey="Steele D">D. Steele</name></author><author><name sortKey="Kirkwood, C D" uniqKey="Kirkwood C">C.D. Kirkwood</name></author><author><name sortKey="Parashar, U D" uniqKey="Parashar U">U.D. Parashar</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Tate, J E" uniqKey="Tate J">J.E. Tate</name></author><author><name sortKey="Burton, A H" uniqKey="Burton A">A.H. Burton</name></author><author><name sortKey="Boschi Pinto, C" uniqKey="Boschi Pinto C">C. Boschi-Pinto</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Lessa, F C" uniqKey="Lessa F">F.C. Lessa</name></author><author><name sortKey="Gould, C V" uniqKey="Gould C">C.V. Gould</name></author><author><name sortKey="Mcdonald, L C" uniqKey="Mcdonald L">L.C. McDonald</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Bruyn, G" uniqKey="De Bruyn G">G. de Bruyn</name></author><author><name sortKey="Saleh, J" uniqKey="Saleh J">J. Saleh</name></author><author><name sortKey="Workman, D" uniqKey="Workman D">D. Workman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sheldon, E" uniqKey="Sheldon E">E. Sheldon</name></author><author><name sortKey="Kitchin, N" uniqKey="Kitchin N">N. Kitchin</name></author><author><name sortKey="Peng, Y" uniqKey="Peng Y">Y. Peng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bezay, N" uniqKey="Bezay N">N. Bézay</name></author><author><name sortKey="Ayad, A" uniqKey="Ayad A">A. Ayad</name></author><author><name sortKey="Dubischar, K" uniqKey="Dubischar K">K. Dubischar</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Zeng, M" uniqKey="Zeng M">M. Zeng</name></author><author><name sortKey="Mao, X H" uniqKey="Mao X">X.H. Mao</name></author><author><name sortKey="Li, J X" uniqKey="Li J">J.X. Li</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Nair, H" uniqKey="Nair H">H. Nair</name></author><author><name sortKey="Nokes, D J" uniqKey="Nokes D">D.J. Nokes</name></author><author><name sortKey="Gessner, B D" uniqKey="Gessner B">B.D. Gessner</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Pendleton, J N" uniqKey="Pendleton J">J.N. Pendleton</name></author><author><name sortKey="Gorman, S P" uniqKey="Gorman S">S.P. Gorman</name></author><author><name sortKey="Gilmore, B F" uniqKey="Gilmore B">B.F. Gilmore</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Seale, A C" uniqKey="Seale A">A.C. Seale</name></author><author><name sortKey="Davies, M R" uniqKey="Davies M">M.R. Davies</name></author><author><name sortKey="Anampiu, K" uniqKey="Anampiu K">K. Anampiu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Anderson, A S" uniqKey="Anderson A">A.S. Anderson</name></author><author><name sortKey="Miller, A A" uniqKey="Miller A">A.A. Miller</name></author><author><name sortKey="Donald, R G" uniqKey="Donald R">R.G. Donald</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Gottlieb, S L" uniqKey="Gottlieb S">S.L. Gottlieb</name></author><author><name sortKey="Deal, C D" uniqKey="Deal C">C.D. Deal</name></author><author><name sortKey="Giersing, B" uniqKey="Giersing B">B. Giersing</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Looker, K J" uniqKey="Looker K">K.J. Looker</name></author><author><name sortKey="Magaret, A S" uniqKey="Magaret A">A.S. Magaret</name></author><author><name sortKey="Turner, K M" uniqKey="Turner K">K.M. Turner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Looker, K J" uniqKey="Looker K">K.J. Looker</name></author><author><name sortKey="Magaret, A S" uniqKey="Magaret A">A.S. Magaret</name></author><author><name sortKey="May, M T" uniqKey="May M">M.T. May</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Newman, L" uniqKey="Newman L">L. Newman</name></author><author><name sortKey="Rowley, J" uniqKey="Rowley J">J. Rowley</name></author><author><name sortKey="Vander Hoorn, S" uniqKey="Vander Hoorn S">S. Vander Hoorn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cates, W" uniqKey="Cates W">W. Cates</name></author><author><name sortKey="Washington, A E" uniqKey="Washington A">A.E. Washington</name></author><author><name sortKey="Rubin, G L" uniqKey="Rubin G">G.L. Rubin</name></author><author><name sortKey="Peterson, H B" uniqKey="Peterson H">H.B. Peterson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xing, W" uniqKey="Xing W">W. Xing</name></author><author><name sortKey="Liao, Q" uniqKey="Liao Q">Q. Liao</name></author><author><name sortKey="Viboud, C" uniqKey="Viboud C">C. Viboud</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, R" uniqKey="Li R">R. Li</name></author><author><name sortKey="Liu, L" uniqKey="Liu L">L. Liu</name></author><author><name sortKey="Mo, Z" uniqKey="Mo Z">Z. Mo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhu, F" uniqKey="Zhu F">F. Zhu</name></author><author><name sortKey="Xu, W" uniqKey="Xu W">W. Xu</name></author><author><name sortKey="Xia, J" uniqKey="Xia J">J. Xia</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Modjarrad, K" uniqKey="Modjarrad K">K. Modjarrad</name></author><author><name sortKey="Moorthy, V S" uniqKey="Moorthy V">V.S. Moorthy</name></author><author><name sortKey="Ben Embarek, P" uniqKey="Ben Embarek P">P. Ben Embarek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Henao Restrepo, A M" uniqKey="Henao Restrepo A">A.M. Henao-Restrepo</name></author><author><name sortKey="Preziosi, M P" uniqKey="Preziosi M">M.P. Preziosi</name></author><author><name sortKey="Wood, D" uniqKey="Wood D">D. Wood</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Vannice, K S" uniqKey="Vannice K">K.S. Vannice</name></author><author><name sortKey="Giersing, B K" uniqKey="Giersing B">B.K. Giersing</name></author><author><name sortKey="Kaslow, D C" uniqKey="Kaslow D">D.C. Kaslow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Black, R E" uniqKey="Black R">R.E. Black</name></author><author><name sortKey="Cousens, S" uniqKey="Cousens S">S. Cousens</name></author><author><name sortKey="Johnson, H L" uniqKey="Johnson H">H.L. Johnson</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Lanzieri, T M" uniqKey="Lanzieri T">T.M. Lanzieri</name></author><author><name sortKey="Dollard, S C" uniqKey="Dollard S">S.C. Dollard</name></author><author><name sortKey="Bialek, S R" uniqKey="Bialek S">S.R. Bialek</name></author><author><name sortKey="Grosse, S D" uniqKey="Grosse S">S.D. Grosse</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="other"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccine</journal-id><journal-id journal-id-type="iso-abbrev">Vaccine</journal-id><journal-title-group><journal-title>Vaccine</journal-title></journal-title-group><issn pub-type="ppub">0264-410X</issn><issn pub-type="epub">1873-2518</issn><publisher><publisher-name>World Health Organization; licensee Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28262332</article-id><article-id pub-id-type="pmc">7131228</article-id><article-id pub-id-type="publisher-id">S0264-410X(16)31205-1</article-id><article-id pub-id-type="doi">10.1016/j.vaccine.2016.10.090</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Giersing</surname><given-names>Birgitte K.</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Vekemans</surname><given-names>Johan</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Nava</surname><given-names>Samantha</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au020"><name><surname>Kaslow</surname><given-names>David C.</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au025"><name><surname>Moorthy</surname><given-names>Vasee</given-names></name><email>moorthyv@who.int</email><xref rid="af005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">⁎</xref></contrib><contrib contrib-type="author"><collab>the WHO Product Development for Vaccines Advisory Committee</collab><xref rid="fn1" ref-type="fn">1</xref></contrib></contrib-group><aff id="af005"><label>a</label>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland</aff><aff id="af010"><label>b</label>University of Texas Medical Branch, Galveston, TX, USA</aff><aff id="af015"><label>c</label>PATH, Seattle, WA 98109, USA</aff><author-notes><corresp id="cor1"><label>⁎</label>Corresponding author at: World Health Organization, Initiative for Vaccine Research, 20 Avenue Appia, 1211-CH 27 Geneva, Switzerland. <email>moorthyv@who.int</email></corresp><fn id="fn1"><label>1</label><p id="np005">WHO Product Development for Vaccines Product Development Advisory Committee: Salim Abdulla (Ifakara Health Institute, Tanzania). Ashish Bavdekar (Kem Hospital and Research Center, Pune, India). Klaus Cichutek (Paul-Ehrlich-Institut, Langen, Germany). Alejandro Cravioto (Global Evaluative Sciences Inc., Seattle, WA, USA). Bernard Fritzell (Independent Consultant, Bordeaux, France) Barney S. Graham (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA). Ruth A. Karron (Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA). Claudio F. Lanata (Instituto de Investigacion Nutricional, Lima, Peru). Yiming Shao (Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China) Peter G. Smith (London School of Hygiene and Tropical Medicine, London, United Kingdom of Great Britain & Northern Ireland.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>3</day><month>3</month><year>2017</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><day>28</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>3</day><month>3</month><year>2017</year></pub-date><volume>37</volume><issue>50</issue><fpage>7315</fpage><lpage>7327</lpage><permissions><copyright-statement>© 2017 World Health Organization</copyright-statement><copyright-year>2017</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab005"><p>The third meeting of WHO’s Product Development for Vaccines Advisory Committee (PDVAC) was held in June 2016, with a remit to revisit the pathogen areas for which significant progress has occurred since recommendations from the 2015 meeting, as well as to consider new advances in the development of vaccines against other pathogens. Since the previous meeting, significant progress has been made with regulatory approvals of the first malaria and dengue vaccines, and the first phase III trials of a respiratory syncytial virus (RSV) vaccine candidate has started in the elderly and pregnant women. In addition, PDVAC has also supported vaccine development efforts against important emerging pathogens, including Middle Eastern Coronavirus (MERS CoV) and Zika virus. Trials of HIV and tuberculosis vaccine candidates are steadily progressing towards pivotal data points, and the leading norovirus vaccine candidate has entered a phase IIb efficacy study. WHO’s Immunization, Vaccine and Biologicals (IVB) department is actively working in several pathogen areas on the recommendation of PDVAC, as well as continuing horizon scanning for advances in the development of vaccines that may benefit low and middle income countries (LMICs), such as the recent licensure of the enterovirus 71 (EV71) vaccine in China. Following on from discussions with WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization, PDVAC will also look beyond licensure and consider data needs for vaccine recommendation and implementation to reduce the delay between vaccine approval and vaccine impact.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Vaccine</kwd><kwd>Product development</kwd><kwd>LMICs</kwd><kwd>Bacterial</kwd><kwd>Viral</kwd><kwd>PDVAC</kwd><kwd>SAGE</kwd></kwd-group></article-meta></front></pmc><affiliations><list><country><li>Suisse</li><li>États-Unis</li></country><region><li>Texas</li><li>Washington (État)</li></region></list><tree><country name="Suisse"><noRegion><name sortKey="Giersing, Birgitte K" sort="Giersing, Birgitte K" uniqKey="Giersing B" first="Birgitte K." last="Giersing">Birgitte K. Giersing</name></noRegion><name sortKey="Moorthy, Vasee" sort="Moorthy, Vasee" uniqKey="Moorthy V" first="Vasee" last="Moorthy">Vasee Moorthy</name><name sortKey="Vekemans, Johan" sort="Vekemans, Johan" uniqKey="Vekemans J" first="Johan" last="Vekemans">Johan Vekemans</name></country><country name="États-Unis"><region name="Texas"><name sortKey="Nava, Samantha" sort="Nava, Samantha" uniqKey="Nava S" first="Samantha" last="Nava">Samantha Nava</name></region><name sortKey="Kaslow, David C" sort="Kaslow, David C" uniqKey="Kaslow D" first="David C." last="Kaslow">David C. Kaslow</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000736 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000736 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:7131228
|texte= Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:28262332" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |